Abstract
Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors. This drug is the first anti-angiogenic small molecule targeting the integrins αvβ3, αvβ5 and α5β1. It was developed by us in the early 90s by a novel procedure, the spatial screening. This strategy resulted in c(RGDfV), the first superactive αvβ3 inhibitor (100 to 1000 times increased activity over the linear reference peptides), which in addition exhibited high selectivity against the platelet receptor αIIbβ3. This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V). This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany). This article describes the chemical development of Cilengitide, the biochemical background of its activity and a short review about the present clinical trials. The positive anti-angiogenic effects in cancer treatment can be further increased by combination with “classical” anti-cancer therapies. Several clinical trials in this direction are under investigation.
Keywords: RGD peptides, integrin antagonists, glioblastoma, N-methylation, conformational restriction, cyclization, Anti-Angiogenic, RGD, ECM, CAM, Angiogenesis, Tumor Vasculature, IMD, NMR, VEGFs, Cilengitide, NSCLC, radio-chemotherapy, ITH, GBM
Anti-Cancer Agents in Medicinal Chemistry
Title: Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
Volume: 10 Issue: 10
Author(s): Carlos Mas-Moruno, Florian Rechenmacher and Horst Kessler
Affiliation:
Keywords: RGD peptides, integrin antagonists, glioblastoma, N-methylation, conformational restriction, cyclization, Anti-Angiogenic, RGD, ECM, CAM, Angiogenesis, Tumor Vasculature, IMD, NMR, VEGFs, Cilengitide, NSCLC, radio-chemotherapy, ITH, GBM
Abstract: Cilengitide, a cyclic RGD pentapeptide, is currently in clinical phase III for treatment of glioblastomas and in phase II for several other tumors. This drug is the first anti-angiogenic small molecule targeting the integrins αvβ3, αvβ5 and α5β1. It was developed by us in the early 90s by a novel procedure, the spatial screening. This strategy resulted in c(RGDfV), the first superactive αvβ3 inhibitor (100 to 1000 times increased activity over the linear reference peptides), which in addition exhibited high selectivity against the platelet receptor αIIbβ3. This cyclic peptide was later modified by N-methylation of one peptide bond to yield an even greater antagonistic activity in c(RGDf(NMe)V). This peptide was then dubbed Cilengitide and is currently developed as drug by the company Merck-Serono (Germany). This article describes the chemical development of Cilengitide, the biochemical background of its activity and a short review about the present clinical trials. The positive anti-angiogenic effects in cancer treatment can be further increased by combination with “classical” anti-cancer therapies. Several clinical trials in this direction are under investigation.
Export Options
About this article
Cite this article as:
Mas-Moruno Carlos, Rechenmacher Florian and Kessler Horst, Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/187152010794728639
DOI https://dx.doi.org/10.2174/187152010794728639 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Approach of Primary Bone Tumours by Bisphosphonates
Current Pharmaceutical Design A Review of Current Animal Models of Osteoarthritis Pain
Current Pharmaceutical Biotechnology Neuroprotective Effects of Quercetin: From Chemistry to Medicine
CNS & Neurological Disorders - Drug Targets Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures
Current Topics in Medicinal Chemistry Evolving Treatment Paradigms for HPV-Related Oropharynx Cancer
Current Cancer Therapy Reviews A Review of Cationic Arylfurans and Their Isosteres: Synthesis and Biological Importance
Current Organic Chemistry Hapten Recognition by T Cells: A Functional and Molecular View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Death-Associated Protein Kinase 1 as a Promising Drug Target in Cancer and Alzheimer’s Disease
Recent Patents on Anti-Cancer Drug Discovery Cachexia and Oxidative Stress in Cancer: An Innovative Therapeutic Management
Current Pharmaceutical Design PPARγ in Angiogenesis and Vascular Development
Current Angiogenesis (Discontinued) Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes
Current Genomics SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer and their Potential Application in Cancer Therapy
Current Pharmaceutical Biotechnology Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry The Prominent Role of Protein-Based Delivery Systems on the Development of Cancer Treatment
Current Pharmaceutical Design